Before giving the drug to you, give it to your miniature organ.
For most of modern medicine, choosing a treatment has meant gathering as much information about a patient as possible and then predicting what is most likely to work.
What disease is it?
What subtype?
What mutations does it carry?
What treatments worked in previous patients with similar disease?
Increasingly, medicine can answer these questions with remarkable precision.
But there is another question that is much more direct:
What happens when this patient’s own living tissue is actually exposed to the drug?
That is the idea behind patient-derived organoids.
A small sample of a patient’s tissue can sometimes be grown in the laboratory into thousands of tiny three-dimensional structures that preserve important characteristics of the original tissue or tumour.
Researchers can then expose those structures to different treatments and watch what happens.
One drug may barely affect them.
Another may stop their growth.
A third may kill a large proportion of the tumour cells.
Instead of relying only on what a cancer should respond to based on its molecular profile, organoids introduce something different:
Functional testing of living biology.
That does not mean that doctors can already grow a perfect miniature copy of every patient and use it to select the correct drug.
They cannot.
But the possibility is becoming increasingly real.
WHAT EXACTLY IS AN ORGANOID?
Despite the nickname “mini-organ,” an organoid is not a complete miniature organ.
It does not contain every structure, blood vessel, nerve, immune cell or mechanical interaction found inside the human body.
Instead, organoids are three-dimensional cellular structures grown under laboratory conditions that reproduce selected architectural, cellular and functional characteristics of the tissue they came from. They can be created from adult tissue stem cells, pluripotent stem cells or patient-derived tissue, depending on the application.
That three-dimensional structure matters.
Traditional cell experiments often grow cells as a flat layer across a plastic dish.
But cells inside the body do not normally exist as isolated flat sheets. They interact with neighbouring cells, extracellular structures, chemical gradients and complex signalling environments.
Organoids attempt to preserve more of that biological context.
For personalised medicine, the particularly interesting version is the patient-derived organoid.
If tissue is collected from a person’s tumour, intestine, airway or another organ, cells from that sample may be expanded into organoids that retain important patient-specific features.
It is not literally a tiny version of the entire person.
But it may be a tiny, living experimental model of one part of their biology.
FROM PATIENT TO LAB: HOW THE IDEA WORKS
Imagine a patient with cancer undergoing surgery or biopsy.
A small portion of the tumour is taken for analysis.
Traditionally, that specimen might be examined under a microscope, analysed for molecular markers and sequenced for important genetic changes.
With an organoid approach, some of those living tumour cells are instead placed into carefully controlled three-dimensional culture conditions.
If successful, they begin to grow.
They self-organise.
They form miniature tumour-like structures.
Once enough material exists, researchers can divide the organoids across different laboratory conditions and expose them to different drugs.
The result is essentially a patient-specific drug experiment.
Treatment A may produce little effect.
Treatment B may significantly reduce organoid viability.
Treatment C may work initially, while a surviving population begins to reveal mechanisms of resistance.
The conceptual workflow is remarkably simple:
Patient tissue → organoid → multiple drug tests → measure response → potentially inform treatment.
The difficult part is making every step sufficiently fast, reproducible and clinically reliable.
CANCER MAY BE THE STRONGEST USE CASE
Cancer is particularly suited to this idea because cancer is extraordinarily heterogeneous.
Two patients can have tumours arising from the same organ and still have biologically different diseases.
Even within one tumour, different populations of cancer cells may behave differently.
Patient-derived tumour organoids can preserve important genetic and phenotypic characteristics of the cancers from which they were produced, which is why they have become major tools in tumour biology, drug screening and precision-oncology research. Living organoid biobanks have also demonstrated that tumour organoids can be expanded and systematically tested against therapies.
This creates an intriguing possibility.
Instead of asking:
“Which treatment normally works for this cancer?”
medicine may increasingly be able to ask:
“Which treatment appears to work against this patient’s cancer?”
That is a much more personalised question.
BEYOND GENETICS: FROM PRECISION DATA TO PRECISION BIOLOGY
Genomic medicine has transformed cancer treatment.
If a tumour contains a particular molecular alteration, that information may help identify a treatment designed to target it.
But a mutation is not the same thing as a treatment response.
Cancer biology is influenced by many interacting factors: gene expression, epigenetics, cell state, tumour heterogeneity, signalling networks, resistance pathways and the surrounding microenvironment.
Two tumours with similar genetic alterations therefore do not necessarily behave identically.
Organoid testing approaches the problem from the opposite direction.
Genomics asks:
What abnormalities are present?
Functional testing asks:
What does the living tumour actually do when we expose it to treatment?
Neither question makes the other obsolete.
The potentially powerful future is their combination.
A tumour could be analysed through pathology, imaging and molecular profiling while, at the same time, a patient-derived organoid undergoes functional drug testing.
The molecular data might explain why a drug should work.
The organoid might provide evidence about whether the patient’s living tumour cells actually respond.
That combination is one of the central ideas behind functional precision oncology.
CAN ORGANOIDS ACTUALLY PREDICT WHAT HAPPENS IN A PATIENT?
This is the question that determines whether organoids remain fascinating research tools or become clinically important decision systems.
And the answer so far is:
Sometimes — but not reliably enough for universal routine use.
A landmark study using organoids derived from metastatic gastrointestinal cancers found substantial similarities between the organoid models and the tumours from which they came, with organoid drug responses corresponding to clinical responses in the studied patients.
Another prospective study in metastatic colorectal cancer found that organoid testing could predict response to irinotecan-based treatments in more than 80% of patients in that dataset without incorrectly excluding patients who benefited. However, the same system did not successfully predict response to another chemotherapy combination, demonstrating that predictive performance can be treatment-specific.
There have also been important negative results.
In an early prospective trial in advanced colorectal cancer, organoids were used to identify potentially active experimental treatments. Although several organoid cultures showed drug sensitivity in the laboratory, the small number of patients who ultimately received organoid-informed therapy did not achieve the hoped-for objective clinical responses.
That result is important.
A tumour inside a human being is more complicated than tumour cells inside a laboratory model.
Drug absorption, metabolism, dose, immune response, blood supply, interactions with surrounding tissues, disease progression and many other factors can alter what happens clinically.
An organoid can reproduce part of the biology.
It cannot yet reproduce the entire patient.
ORGANOID BIOBANKS: LIBRARIES OF LIVING DISEASE
One organoid represents one biological model.
Thousands of organoids from hundreds or thousands of patients create something far more powerful:
A living biobank.
Unlike a traditional tissue archive consisting mainly of preserved samples, an organoid biobank can contain renewable, living models that can be expanded, studied and exposed to new drugs.
Early colorectal-cancer organoid biobanks demonstrated that collections of patient-derived models could preserve important molecular diversity between tumours while also supporting systematic drug screening.
This creates several possibilities.
Researchers can compare drug responses across genetically different tumours, search for mechanisms of resistance, investigate uncommon disease subtypes and test experimental combinations across a biologically diverse population before moving into larger studies.
Rare diseases may particularly benefit.
Instead of losing an exceptionally uncommon biological sample once an experiment is complete, researchers may be able to maintain a renewable living model for repeated investigation.
In that sense, future biobanks may store more than DNA and frozen tissue.
They may store living representations of human disease.
ORGANOIDS-ON-CHIP: MAKING THE MINIATURE WORLD MORE REALISTIC
A conventional organoid still sits in an artificial laboratory environment.
The human body is different.
Blood flows.
Pressure changes.
Nutrients arrive continuously.
Waste products are removed.
Cells experience mechanical forces.
Different tissues communicate with one another.
One emerging solution is to combine organoids with microfluidic chip technology.
These systems contain tiny engineered channels through which fluids can move around or through living tissue models.
Researchers can use them to create controlled flow, nutrient delivery, biochemical gradients and mechanical stimulation. More sophisticated systems are being developed to introduce vascular-like interfaces or interactions between different tissue models.
The organoid provides biological complexity.
The chip provides environmental control.
Together, they may produce a model that behaves more like tissue inside a living organism than an organoid sitting passively in a dish.
This is where the concept begins to move from a simple “mini-organ” toward a miniature physiological test environment.
THE IMMUNE SYSTEM IS ONE OF THE BIGGEST MISSING PIECES
Cancer treatment makes another limitation particularly obvious.
A tumour is not just tumour cells.
It contains immune cells, stromal cells, fibroblasts, vascular cells and many signalling molecules collectively forming the tumour microenvironment.
Many conventional tumour organoids do not preserve this entire ecosystem.
That becomes a major problem when attempting to test immunotherapy.
A therapy designed to activate immune cells cannot be modelled accurately if the relevant immune cells are missing.
Researchers are therefore developing immune-organoid co-cultures, in which patient-derived tumour organoids are combined with immune cells and, in increasingly sophisticated models, other components of the tumour microenvironment.
The ambition is significant.
A future system might not simply ask whether a drug kills cancer cells.
It might ask whether a patient’s immune cells recognise the tumour, whether treatment strengthens that attack, whether the tumour escapes it and which combination restores immune activity.
That would move organoid testing much closer to modelling the real biological battlefield inside cancer.
But immune-competent organoid systems remain considerably more complex and less standardised than basic tumour organoids.
CRISPR + ORGANOIDS: EDIT THE MINIATURE DISEASE AND SEE WHAT CHANGES
Organoids can also be combined with gene-editing technologies such as CRISPR.
This changes their role from passive disease models into experimental biological systems.
Researchers can alter specific genes within an organoid and observe what happens.
Does the tissue start growing abnormally?
Does a tumour become resistant to a drug?
Does removing a gene make cancer cells vulnerable to another treatment?
Can a disease-causing mutation be experimentally corrected?
Modern CRISPR screens in patient-derived organoids are being investigated to identify cancer dependencies, study tumour evolution and uncover genes involved in treatment sensitivity and resistance.
The combination is powerful because it connects genotype to function.
Instead of merely discovering that a mutation exists, researchers can manipulate that mutation inside patient-relevant living tissue and examine the consequences.
That could help distinguish mutations that simply accompany disease from biological changes that actively drive it.
THIS IS NOT ONLY ABOUT CANCER
Cancer receives much of the attention because drug selection is such an urgent clinical problem, but organoids are being developed across many areas of medicine.
Intestinal, airway, liver, kidney, brain, retinal and other organoid systems are being used to study human development, inherited disease, infection, inflammatory disorders, neurological conditions, toxicity and drug responses.
One particularly instructive example comes from cystic fibrosis.
Patient-derived intestinal organoids can undergo a laboratory swelling test that reflects the function of the CFTR protein. Researchers can expose those organoids to CFTR-modulating drugs and measure whether function improves. Importantly, organoid responses have shown correlations with clinical treatment responses, including in work examining uncommon CFTR variants.
That is close to the fundamental vision of personalised organoid medicine:
Take a patient’s cells, test treatment functionally and use the result to help understand whether that patient may benefit.
Applications in inflammatory bowel disease, liver and kidney disorders, infections, neurodevelopmental disease and rare genetic disorders are at different stages of maturity, but the platform is much broader than oncology.
AI COULD BECOME THE ORGANOID INTERPRETER
There is another problem.
Once organoid testing becomes large-scale, humans cannot realistically inspect every miniature tissue manually.
Imagine hundreds of organoids from one patient exposed to dozens of drugs at multiple doses while cameras repeatedly record their behaviour.
Each experiment could generate enormous amounts of information.
Organoid diameter.
Shape.
Growth rate.
Cell death.
Structural collapse.
Movement.
Fluorescence.
Molecular signals.
Changes over time.
This is precisely the kind of high-dimensional information that artificial intelligence and machine-learning systems can analyse.
Recent work is exploring AI-assisted organoid imaging for segmentation, tracking, viability assessment, morphological analysis and drug-response interpretation. Computational approaches are also being investigated for combining organoid measurements with molecular and pharmacological datasets.
The eventual workflow could become increasingly automated.
A robotic system grows organoids.
Imaging systems monitor them continuously.
Different drugs are delivered automatically.
AI measures thousands of subtle changes that would be difficult for a person to quantify consistently.
The output becomes a patient-specific drug-response profile.
The futuristic part is not simply growing the organoid.
It is building the automated biological testing system around it.
COULD ORGANOIDS REDUCE ANIMAL TESTING?
Organoids could also change how new drugs are developed before they ever reach patients.
Traditional preclinical testing often moves from simplified cell systems into animal models before human trials.
But animal biology is not human biology.
Organoids offer a way to test therapies directly in human-derived tissue models.
That could be particularly useful for studying human-specific toxicity, disease biology and treatment response.
Newer drug-development strategies increasingly consider organoids and other advanced human tissue systems as part of a broader group of alternative experimental models.
That does not mean organoids can simply replace every animal experiment.
An isolated organoid cannot fully reproduce whole-body metabolism, circulation, endocrine signalling, immune responses, behaviour or interactions among distant organs.
The more realistic future is likely to involve organoids reducing dependence on some animal experiments while helping researchers decide which drug candidates deserve further investigation.
Better human models earlier in development could mean fewer weak candidates progressing to later stages.
WHAT IS REAL TODAY?
Patient-derived organoids can already be grown from many normal and diseased human tissues. Tumour organoids can preserve important genetic and phenotypic features of the cancers from which they originate. Living organoid biobanks exist as research platforms. Organoids are routinely used experimentally for disease modelling, drug discovery, toxicity studies and treatment-response research.
There is also clinical evidence that organoid responses can correlate with patient responses for particular diseases and therapies, including studies in gastrointestinal cancers and cystic fibrosis.
Prospective studies are continuing to test whether organoid-guided treatment can improve clinical decision-making, including trials combining molecular profiling with patient-derived organoid drug screening and trials directly comparing organoid-guided therapy with physician-selected treatment.
So the technology is no longer simply theoretical.
But its clinical role is still being defined.
WHAT IS NOT FULLY REAL YET?
We cannot routinely grow a perfect organoid from every patient.
We cannot reliably reproduce every blood vessel, immune interaction, nerve connection or systemic effect of the human body.
Organoid culture can fail.
Different laboratories can produce somewhat different models.
Growing sufficient tissue and completing drug testing can take valuable time.
Cancer may evolve while the model is being produced.
The piece of tumour sampled may not perfectly represent every tumour site in the patient.
And there is still no universal rule stating that the drug that performs best in an organoid will perform best in the patient.
Standardisation, scalability, cost, turnaround time, biological complexity and prospective clinical validation remain major barriers to widespread implementation.
Organoids therefore do not replace pathology.
They do not replace medical imaging.
They do not replace genomic testing.
They do not replace clinical trials.
And they certainly do not guarantee the correct treatment.
At least not today.
THE NEXT STEP: FROM PRECISION MEDICINE TO FUNCTIONAL PRECISION MEDICINE
The first generation of personalised medicine was largely about identifying differences between patients.
The next generation may increasingly be about testing those differences directly.
Imagine a future cancer work-up.
The biopsy confirms the diagnosis.
Sequencing identifies the mutations.
Molecular profiling reveals the signalling pathways.
An organoid reproduces part of the tumour’s living biology.
An immune co-culture examines interaction with the patient’s immune system.
A microfluidic chip recreates elements of the tumour environment.
Automated imaging measures treatment response.
AI integrates those results with molecular and clinical data.
And before the final treatment decision is made, several therapies have already been experimentally tested against a living model derived from the patient.
That would represent a profound shift.
From:
“Based on patients like you, this drug should work.”
toward:
“We tested several options on tissue derived from your disease. This is what happened.”
Medicine would still need clinical judgment, validated trials, pathology, imaging and molecular information.
But it would have something new alongside them:
A functional preview of treatment response.
THE BIGGEST IDEA
Organoids represent a shift from precision medicine based primarily on information about biology toward precision medicine that can also experimentally interrogate living biology itself.
The future may therefore not be:
Treat first. See what happens later.
It may increasingly become:
Test first. Learn from the miniature tissue. Then decide.
That future is not completely here.
But parts of it already are.
FACT BASE
Organoids are not complete miniature organs. They are three-dimensional laboratory-grown tissue models that reproduce selected structural and functional characteristics of human tissues.
Patient-derived tumour organoids can retain important characteristics of the original cancer. Studies have demonstrated preservation of tumour-associated genetic and phenotypic features and have enabled patient-specific drug testing.
Treatment prediction is promising but inconsistent. Organoid responses have correlated with clinical response for some cancer therapies, while other treatments and prospective organoid-guided approaches have shown weaker or negative results.
Functional testing can complement genomic testing. Genomics identifies molecular abnormalities, while patient-derived experimental models directly measure biological response to treatment. Current functional-precision-oncology research is investigating how these approaches can be combined.
Advanced organoid systems are becoming more sophisticated. Immune co-culture, microfluidic organoid-on-chip systems, CRISPR screening and AI-assisted image analysis are being developed to overcome limitations of conventional organoids.
Organoid-based functional testing is already relevant outside cancer. Patient-derived intestinal organoids have been used to measure CFTR function and treatment responses in cystic fibrosis, including research involving rare genetic variants.
Routine organoid-guided treatment for every patient is not yet established. Culture success, turnaround time, cost, assay standardisation, tumour heterogeneity, incomplete modelling of the microenvironment and the need for stronger prospective clinical validation remain significant barriers.
REFERENCES
- Wang D, Villenave R, Stokar-Regenscheit N, et al. Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges. Nature Reviews Drug Discovery. 2026;25:204–226. DOI: 10.1038/s41573-025-01317-y.
- van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161(4):933–945. DOI: 10.1016/j.cell.2015.03.053.
- Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920–926. DOI: 10.1126/science.aao2774.
- Ooft SN, Weeber F, Dijkstra KK, et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Science Translational Medicine. 2019;11(513):eaay2574. DOI: 10.1126/scitranslmed.aay2574.
- Ooft SN, Weeber F, Schipper L, et al. Prospective experimental treatment of colorectal cancer patients based on organoid drug responses. ESMO Open. 2021;6(3):100103. DOI: 10.1016/j.esmoop.2021.100103.
- Yao N, Jing N, Lin J, et al. Patient-derived tumor organoids for cancer immunotherapy: culture techniques and clinical application. Investigational New Drugs. 2025;43(2):394–404. DOI: 10.1007/s10637-025-01523-w.
- Papamichail L, Koch LS, Veerman D, Broersen K, van der Meer AD. Organoids-on-a-chip: microfluidic technology enables culture of organoids with enhanced tissue function and potential for disease modeling. Frontiers in Bioengineering and Biotechnology. 2025;13. DOI: 10.3389/fbioe.2025.1515340.
- Railean V, Rodrigues CS, Pankonien I, et al. Personalized Medicine in Cystic Fibrosis: Characterization of Eight Rare CFTR Variants in Intestinal Organoids and Cellular Models. Molecular Diagnosis & Therapy. 2026;30(1):111–136. DOI: 10.1007/s40291-025-00806-5.
- Patient-Derived Organoid-Based CRISPR Screens in Cancer Research: Applications, Advances, and Challenges. Cancer Medicine. 2026. DOI: 10.1002/cam4.72112.
- Xu Y, Fan S, Chen Y, et al. The application and progress of AI-based image analysis in tumor organoid research. iScience. 2026;29(8):116756. DOI: 10.1016/j.isci.2026.116756.
- Human organoids: Fit for drug discovery? Stem Cell Reports. 2026;21(6):102898. DOI: 10.1016/j.stemcr.2026.102898.
- Ex vivo drug screening on patient-derived tumor material to advance functional precision in oncology: an overview on current approaches and unresolved challenges. Cancer Treatment Reviews. 2026;143:103072. DOI: 10.1016/j.ctrv.2025.103072.